Cytokinetics, (NASDAQ:CYTK) Receiving Very Favorable News Coverage, Study Shows
News coverage about Cytokinetics, (NASDAQ:CYTK) has trended very positive on Friday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytokinetics, earned a news sentiment score of 0.62 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 25 out of 100, indicating that recent press coverage is very unlikely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Cytokinetics, Incorporated (NASDAQ:CYTK) Receives “Buy” Rating from Cowen and Company (americanbankingnews.com)
- Cytokinetics, Incorporated (CYTK) Releases Earnings Results, Misses Expectations By $0.03 EPS (americanbankingnews.com)
- Cytokinetics Reports Second Quarter 2017 Financial Results (biospace.com)
- Cytokinetics (CYTK) Reports Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients … – StreetInsider.com (streetinsider.com)
- Cytokinetics, Incorporated (NASDAQ:CYTK) Trading Up – Insiders Selling, Short Interest Growing – First News 24 (firstnewspaper24.com)
Shares of Cytokinetics, (CYTK) traded down 2.407% during trading on Friday, reaching $13.175. 404,374 shares of the company were exchanged. The firm’s market capitalization is $635.26 million. The firm’s 50 day moving average is $13.67 and its 200 day moving average is $12.96. Cytokinetics, has a 1-year low of $8.51 and a 1-year high of $17.20.
Cytokinetics, (NASDAQ:CYTK) last posted its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.03. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 17.38%. The company had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $5.28 million. On average, equities analysts anticipate that Cytokinetics, will post ($2.02) EPS for the current fiscal year.
CYTK has been the topic of several research reports. Zacks Investment Research downgraded shares of Cytokinetics, from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 4th. HC Wainwright set a $26.00 price target on shares of Cytokinetics, and gave the stock a “buy” rating in a research note on Thursday. ValuEngine raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub raised shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Cowen and Company reissued a “buy” rating and set a $19.00 price target on shares of Cytokinetics, in a research note on Friday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $21.20.
ILLEGAL ACTIVITY WARNING: “Cytokinetics, (NASDAQ:CYTK) Receiving Very Favorable News Coverage, Study Shows” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/08/04/cytokinetics-nasdaqcytk-receives-daily-media-sentiment-rating-of-0-62-updated-updated-updated.html.
In other Cytokinetics, news, CEO Robert I. Blum sold 5,000 shares of Cytokinetics, stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $13.79, for a total value of $68,950.00. Following the transaction, the chief executive officer now owns 84,785 shares in the company, valued at $1,169,185.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 15,000 shares of company stock worth $197,750 in the last quarter. 7.20% of the stock is owned by insiders.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.
Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.